Immunoglobulin Market - Global Market Share, Trends, Analysis and Forecast, 2023-2032

The global immunoglobulin market size was estimated to be US$ 12.5 billion in 2021 and is expected to grow at a CAGR of 7% between 2023 to 2032.

Immunoglobulins are characterized as a type of glycoprotein molecules that are produced by white blood cells (WBCs) or plasma. They are also known as antibodies that identify antigens such as bacteria and viruses by binding to them and also neutralizing them. In many people, immunoglobulins need to be administered via different routes for the body to neutralize pathogens and to maintain immunity.

The property of Immunoglobulins to correctly identify and bind to antigens also helps in diagnosis of multiple diseases such as immune deficiencies, allergies and auto immune diseases namely celiac disease, lupus and arthritis. Based on biological structure, target specificity, distribution and characteristics different immunoglobulins are classified accordingly.

There is a great demand for immunoglobulins for treatment and diagnostic purposes due to increased awareness and greater efficiency. Its proven efficiency in treating rare immunodeficiency disorders like chronic inflammatory demyelinating polyneuropathy (CIDP) is bolstering the market growth.

Global Immunoglobulin market dynamics

Rise in the incidences of autoimmune and chronic diseases

The rising number of patients suffering from autoimmune diseases such as multiple myeloma, Waldenstrom macroglobulinemia, hypogammaglobulinemia and chronic inflammatory demyelinating polyneuropathy (CIDP) will drive market growth

Increase in geriatric population

In many developed countries the population of people over 60 years in steadily increasing. As the persons age increases the incidences of autoimmune and chronic diseases also increase.

Rise in the prevalence of sedentary lifestyle

As more and more people are consuming fast foods as a result of increased urbanization, stressful and sedentary lifestyles this market is predicted to grow.

Increase in the number of research and development activities

The number of research and development activities for autoimmune disorders has increased and there is an increase in investment for developing new and advanced technologies that will bolster this market growth during the forecast period.

COVID-19 impact on global market

The global pandemic of COVID-19 has offered pharmaceutical companies numerous opportunities to increase their research and development budgets in order to offer treatment options to critically ill COVID-19 patients. Immunoglobulin therapy for COVID-19 infection has shown to be favorable in treating COVID-19. Also, the increase of activities by the regulatory authorities to approve new treatments has further bolstered this market growth.

Challenges in the global Immunoglobulin market

High costs in manufacturing

Developing immunoglobulins is a highly complex and costly process that requires significant investments, clinical trial expertise, quality systems, scientific standards and technical capabilities. Immunoglobulin manufacturers are required to invest in clinical trials and post-approval safety monitoring programs due to stringent regulations required by the regulators.

Lack of skilled professionals

There is a shortage of skilled healthcare professionals and also lack of training to administer immunoglobulin therapies. Also, there are few apprehensions about the safety of this therapy among the healthcare community. Therefore, the lack of awareness and skills could be restraining factors for market growth.

Immunoglobulin Market Share Analysis, by Geography (2022)

The major players operating in the immunoglobulins market are Baxter, Biotest AG, China Biologic Products Holdings Inc, CSL Limited, Grifols S.A., Kedrion S.p.A, Octapharma, GREEN CROSS CORP, Coram LLC, Momenta Pharmaceuticals, Option Care Enterprises Inc, ADMA Biologics Inc, Gentian Diagnostics AS, Mabtech, Mitra & Co. Pvt. Ltd, Cygnus Technologies, Kamada Pharmaceuticals, HAFFKINE BIO-PHARMACEUTICAL CORPORATION LTD, Kedrion Biopharma Inc, Hualan Biological Engineering Inc and others.

Market Segmentation as below:

By Product

• IgA
• IgG
• IgM
• IgE
• IgD

By Application

• Hypogammaglobulinemia
• Chronic Inflammatory Demyelinating Polyneuropathy
• Immunodeficiency Disease
• Myasthenia Gravis
• Multifocal Motor Neuropathy
• Idiopathic Thrombocytopenic Purpura
• Inflammatory Myopathies
• Specific Antibody Deficiency
• Guillain‐Barré Syndrome

By Mode of Delivery

• Intravenous
• Subcutaneous

By Geography

• North America
  • United States
  • Canada
  • Rest of North America
• Europe
  • Germany
  • United Kingdom
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • India
  • China
  • Australia
  • Rest of Asia Pacific
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • South Africa
  • Rest of the Middle East & Africa
• South America
  • Brazil
  • Rest of South America